



BioAlliance Pharma announces that it has initiated arbitration proceedings in the International Chamber of Commerce against SpePharm and SpeBio

Paris, April 1, 2009 – BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, announces that it has filed a request for arbitration against SpePharm and SpeBio with the Arbitration Court of the International Chamber of Commerce in order to obtain reparation for the damage caused to it by non-compliance with contractual obligations and delays in the marketing and sales of Loramyc® in Europe. BioAlliance estimates that the damages owed to it are at least 45M€.

BioAlliance received today from SpePharm and SpeBio a letter containing an ultimatum and threatening to commence a press campaign denigrating Loramyc®, its potential and its reputation. Accordingly BioAlliance decided to make public the fact that it has initiated proceedings with the International Chamber of Commerce.

This action follows the complaint it filed with the Commercial Court of Paris and the termination of the license agreement with SpeBio dated February 27, 2009. Prior to doing so, BioAlliance sought an amicable resolution with SpePharm and SpeBio of this conflict which is related to their breach contractual obligations.

In the meantime, SpePharm and SpeBio have withdrawn the summary proceedings they filed in the Netherlands.

Dominique Costantini, President and CEO of BioAlliance, emphasizes: *“SpePharm and SpeBio have refused to ensure, as provided by contract, the distribution of Loramyc® for a period of six months subsequent to termination. We have therefore immediately put in place all the necessary structures in order to ensure the continuity of patient treatment in the countries where the product has been marketed by SpeBio. We wish to defend the interests of BioAlliance and for Loramyc® we are now actively looking for an industrial partner in Europe present in supportive care/oncology”.*

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com